Artificial Intelligence in Drug Discovery
AI drug discovery is studied across target identification, molecule design, virtual screening, ADMET prediction and clinical trial design. The report covers software platforms, discovery…
AI drug discovery is studied across target identification, molecule design, virtual screening, ADMET prediction and clinical trial design. The report covers software platforms, discovery…
Compound screening libraries are studied by library type, including diversity, focused, fragment, natural product and DNA-encoded collections. The report covers purchase and access models…
Humanized animal models are assessed by model type, covering humanized immune system, liver and gene-humanized mice and rats. Oncology, immunology, infectious disease and drug metabolism…
Molecular glues are examined as a degrader modality that redirects E3 ligases to new protein targets. The report reviews discovery approaches, approved and pipeline compounds, screening…
Organ-on-chip is examined as a technology platform spanning liver, lung, kidney, gut, heart and multi-organ systems. The study covers chips, instruments and services, uses in toxicology and…
Organoids are studied by tissue type, including intestinal, liver, kidney, lung, tumor and brain models, and by use in disease modeling, drug screening and personalized medicine. Culture…
PROTACs and related targeted protein degraders are reviewed from E3 ligase biology to clinical development. The study covers pipeline programs by therapeutic area, chemistry and linker…
Undruggable target discovery is reviewed across the approaches that reach transcription factors, scaffolding proteins and other difficult targets. Covalent chemistry, protein degradation…